Exploring the potential of lecithin/chitosan nanoparticles in enhancement of antihypertensive efficacy of hydrochlorothiazide

Journal of Microencapsulation

Volumn 29, Issue 8, 2012, Pages 805-812

  Chadha, Renu ^a   Bhandari, Swati ^a   Kataria, Darpan ^a   Gupta, Sushma ^a   Jain, Dharamvir Singh ^b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Nanotechnology; Pharmacodynamics; Poorly water soluble; Solvent evaporation; Zeta potential

Indexed keywords

BETA CYCLODEXTRIN; HYDROCHLOROTHIAZIDE; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FEMALE; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HYPERTENSION; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHITOSAN; HYDROCHLOROTHIAZIDE; LECITHINS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84869445535     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.692399     Document Type: Article

References (22)

1. Chadha R, Arora P, Bhandari S, Jain DVS. Effect of hydrophilic polymer on complexing efficiency of cyclodextrins towards efavirenz-characteriza-tion and thermodynamic parameters. J Incl Phenom Macrocycl Chem, 2012;72:275-87.
2. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm, 2009;73:1-15.
3. Chandy T, Sharma CP. Chitosan\As a biomaterial. Artif Cells Blood Substitut Immobil Biotech, 1990;18:1-24.
4. Ellenhorn MJ, Barceloux DG. 1988. Medical toxicology-diagnosis and treatment of human poisoning. New York: Elsevier Science Publishing Co., Inc.
5. Hollabaugh CB, Burt LH, Walsh AP. Carboxymethyl cellulose..Uses and applications. Ind Eng Chem, 1945;37:943-7.
6. Kearney PM, Whelton M, Reynolds K. Global burden of hypertension: Analysis of worldwide data. Lancet, 2005;365:217-23. (Pubitemid 40138015)
7. Kh R, Khullarb M, Kashyapb M, Pandhi P, Uppala R. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens, 2000;18:919-26. (Pubitemid 30459494)
8. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: Estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull, 1995;43:1412-15.
9. Magenheim B. A new in vitro technique for the evaluation of drug release profile from colloidal carriers ultrafiltration technique at low pressure. Int J Pharm, 1993;94:115-23. (Pubitemid 23204057)
10. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 2001;47:3-19. (Pubitemid 32209229)
11. Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161-77. (Pubitemid 30326695)
12. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev, 2003;55:329-47. (Pubitemid 36297053)
13. Pires MAS, Santos RAS, Sinisterra RD. Pharmaceutical composition of Hydrochlorothiazide:β-Cyclodextrin: Preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation. Molecules, 2011;16:4482-99.
14. Redhead HM, Davis SS, Illum L. Drug delivery in poly (lactide- coglycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J Control Release, 2001;70:353-63. (Pubitemid 32155458)
15. Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Delivery Rev, 2010;62(4-5): 560-75.
16. Shabouri MHE. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm, 2002;249:101-8.
17. Shu XZ, Zhu KJ. Controlled drug release properties of ionically cross-linked chitosan beads: The influence of anion structure. Int J Pharm, 2002;233:217-25. (Pubitemid 34230434)
18. Sonvico F, Cagnania A, Rossi A, Motta S, Di Bari MT, Cavatortab F, Alonso MJ, Deriub A, Colomboa P. Formation of self-organized nano-particles by lecithin/chitosan ionic interaction. Int J Pharm, 2006;324:67-73. (Pubitemid 44548291)
19. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 2001;70:1-20. (Pubitemid 32144788)
20. TSRL inc. 2011. BCS (Biopharmaceutics Classification System). Available at: http://69.20.123.154/services/bcs/results.cfm. Accessed 15 December 2011.
21. Vervaet C, Baert L, Remon JP. Enhancement of in vitro drug release by using polyethylene glycol 400 and PEG-40 hydrogenated castor oil in pellets made by extrusion/spheronisation. Int J Pharm, 1994;108:207-12. (Pubitemid 24223175)
22. Vervaet C, Remon JP. Bioavailability of hydrochlorothiazide from pellets, made by extrusion/spheronisation, containing polyethylene glycol 400 as a dissolution enhancer. Pharm Res, 1997;14:1644-6. (Pubitemid 28009220)